Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.

Cornered in a part of Downtown Los Angeles swamped in contemporary art museums and performance centers, REDCAT has become a ...

The reported valuation aligns with where Manus had been headed before Meta intervened. The company had been raising new funds ...

The lack of gains in productivity from AI could stall adoption and burst the economic bubble. Is there a rational explanation?

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Cathie Wood’s ARK Investment Management sharply increased its exposure to AI-driven biotechnology and cryptocurrency during ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Khadija Khartit is a strategy, investment, and funding expert, and an educator of fintech and strategic finance ...

Value ETFs allow investment in multiple undervalued stocks with one transaction. Vanguard Value ETF offers low fees and tracks the CRSP Large Cap Value index effectively. Value ETFs provide ...